These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7926293)

  • 1. Quantitation of glutamic acid decarboxylase autoantibody levels in prospectively evaluated relatives of patients with type I diabetes.
    Yu L; Gianani R; Eisenbarth GS
    Diabetes; 1994 Oct; 43(10):1229-33. PubMed ID: 7926293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.
    Verge CF; Gianani R; Kawasaki E; Yu L; Pietropaolo M; Jackson RA; Chase HP; Eisenbarth GS
    Diabetes; 1996 Jul; 45(7):926-33. PubMed ID: 8666144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of anti-GAD antibodies with islet cell antibodies and insulin autoantibodies in first-degree relatives of type I diabetic patients.
    Roll U; Christie MR; Standl E; Ziegler AG
    Diabetes; 1994 Jan; 43(1):154-60. PubMed ID: 8262311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1.
    Yu L; Cuthbertson DD; Maclaren N; Jackson R; Palmer JP; Orban T; Eisenbarth GS; Krischer JP;
    Diabetes; 2001 Aug; 50(8):1735-40. PubMed ID: 11473032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of antibodies to GAD-65 and IA-2ic can replace the islet-cell antibody assay to identify subjects at risk of type 1 diabetes mellitus.
    Hatziagelaki E; Jaeger C; Petzoldt R; Seissler J; Scherbaum WA; Federlin K; Bretzel RG
    Horm Metab Res; 1999 Oct; 31(10):564-9. PubMed ID: 10596966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of type 1 (insulin-dependent) diabetes mellitus in high risk individuals.
    Thivolet CH; Tappaz M; Durand A; Petersen J; Stefanutti A; Chatelain P; Vialettes B; Scherbaum W; Orgiazzi J
    Diabetologia; 1992 Jun; 35(6):570-6. PubMed ID: 1612231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies.
    Pietropaolo M; Yu S; Libman IM; Pietropaolo SL; Riley K; LaPorte RE; Drash AL; Mazumdar S; Trucco M; Becker DJ
    Pediatr Diabetes; 2005 Dec; 6(4):184-92. PubMed ID: 16390386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited loss of tolerance to islet autoantigens in ICA+ first degree relatives of patients with type I diabetes expressing the HLA dqb1*0602 allele.
    Gianani R; Verge CF; Moromisato-Gianani RI; Yu L; Zhang YJ; Pugliese A; Eisenbarth GS
    J Autoimmun; 1996 Jun; 9(3):423-5. PubMed ID: 8816981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives.
    Bingley PJ; Christie MR; Bonifacio E; Bonfanti R; Shattock M; Fonte MT; Bottazzo GF; Gale EA
    Diabetes; 1994 Nov; 43(11):1304-10. PubMed ID: 7926304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Islet cell antibodies are less predictive of IDDM among unaffected children in the general population than in sibs of children with diabetes. The Childhood Diabetes in Finland Study Group.
    Knip M; Karjalainen J; Akerblom HK
    Diabetes Care; 1998 Oct; 21(10):1670-3. PubMed ID: 9773728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials.
    Bingley PJ; Williams AJ; Gale EA
    Diabetes Care; 1999 Nov; 22(11):1796-801. PubMed ID: 10546010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to a 38-kDa glycosylated islet cell membrane-associated antigen in (pre)type 1 diabetes: association with IA-2 and islet cell autoantibodies.
    Winnock F; Christie MR; Batstra MR; Aanstoot HJ; Weets I; Decochez K; Jopart P; Nicolaij D; Gorus FK;
    Diabetes Care; 2001 Jul; 24(7):1181-6. PubMed ID: 11423499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase.
    Myers MA; Rabin DU; Rowley MJ
    Diabetes; 1995 Nov; 44(11):1290-5. PubMed ID: 7589826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives.
    Dittler J; Seidel D; Schenker M; Ziegler AG
    Diabetes; 1998 Apr; 47(4):592-7. PubMed ID: 9568692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.
    Verge CF; Stenger D; Bonifacio E; Colman PG; Pilcher C; Bingley PJ; Eisenbarth GS
    Diabetes; 1998 Dec; 47(12):1857-66. PubMed ID: 9836516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.
    Bingley PJ; Bonifacio E; Williams AJ; Genovese S; Bottazzo GF; Gale EA
    Diabetes; 1997 Nov; 46(11):1701-10. PubMed ID: 9356015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte antigen identity and DQ risk alleles in autoantibody-positive siblings of children with IDDM are associated with reduced early insulin response. Childhood Diabetes in Finland (DiMe) Study Group.
    Veijola R; Vähäsalo P; Tuomilehto-Wolf E; Reijonen H; Kulmala P; Ilonen J; Akerblom HK; Knip M
    Diabetes; 1995 Sep; 44(9):1021-8. PubMed ID: 7657023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined analysis of islet cell antibodies that cross-react with mouse pancreas, antibodies to the M(r) 64,000 islet protein, and antibodies to glutamate decarboxylase in type I diabetic patients.
    Chaillous L; Delamaire M; Martignat L; Maugendre D; Marre M; Mathieu E; Limal JM; Charbonnel B; Allannic H; Saï P
    Diabetes Care; 1994 Oct; 17(10):1115-23. PubMed ID: 7821130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of islet cell cytoplasmic antibodies and autoantibodies to glutamate decarboxylase in relatives of patients with type 1 (insulin-dependent) diabetes.
    Bergerot I; Souchier C; Thivolet C
    C R Acad Sci III; 1993 Nov; 316(11):1368-73. PubMed ID: 8087616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity at diagnosis of combined beta-cell autoantibodies in insulin-dependent diabetic children. French Registry of IDDM in Children Study Group.
    Ongagna JC; Levy-Marchal C
    Diabetes Metab; 1997 Apr; 23(2):155-60. PubMed ID: 9137905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.